Clinica Chimica Acta最新文献

{"title":"BDNF biosensors for neurodegenerative disease","authors":"Tamara Nazar Saeed ,&nbsp;Ali Fawzi Al-Hussainy ,&nbsp;Gaurav Sanghvi ,&nbsp;Suhas Ballal ,&nbsp;Abhayveer Singh ,&nbsp;A. Sabarivani ,&nbsp;Swati Mishra ,&nbsp;Jasur Rizaev ,&nbsp;Sada Ghalib Taher ,&nbsp;Mariem Alwan ,&nbsp;Mahmood Jawad ,&nbsp;Hiba Mushtaq","doi":"10.1016/j.cca.2025.120412","DOIUrl":"10.1016/j.cca.2025.120412","url":null,"abstract":"<div><div>The brain-derived neurotrophic factor (BDNF) is essential for neuronal health and function. Dysregulated BDNF levels have been correlated with the etiology of several neurological disorders, including Alzheimer’s and Parkinson’s diseases. Recently, biomarkers of central nervous system (CNS) inflammatory responses have been discovered in a variety of body fluids, including blood, cerebrospinal fluid (CSF), and tears. Personalized medicine and screening programs will become feasible once biosensing technologies advance sufficiently and are widely implemented in communities. This multidisciplinary review provides an overview of the molecular structure and synthesis of BDNF, emphasizing the complexity and intricate regulation of this crucial neurotrophic factor, as well as exploring the potential of BDNF as a biomarker for neurological conditions. It focuses on its role in disease progression and its utility in early disease detection using aptasensors and immunosensors. We also discuss the challenges associated with utilizing BDNF as a biomarker, such as its complex regulation and the need for sensitive and specific detection methods by electrochemical and optical transducers. Furthermore, we highlight the potential of biosensors to overcome these challenges by enabling real-time, non-invasive, and point-of-care (POC) monitoring of BDNF levels.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"576 ","pages":"Article 120412"},"PeriodicalIF":3.2,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144229684","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nanosensing for tramadol detection: Innovative opioid analysis","authors":"Ilghar Zeinaly ,&nbsp;Ali Ahmadalipour ,&nbsp;Mohammad Mahdi Heidari ,&nbsp;Shahab Masoumi ,&nbsp;Arash Mohagheghi ,&nbsp;Ahmad Mobed","doi":"10.1016/j.cca.2025.120414","DOIUrl":"10.1016/j.cca.2025.120414","url":null,"abstract":"<div><div>Tramadol, a widely used analgesic, plays a significant role in pain management but poses risks of misuse and addiction, necessitating accurate detection methods. Traditional analytical techniques for opioid determination, such as chromatography and mass spectrometry, often face limitations, including lengthy processing times, high costs, and the need for specialized equipment. In contrast, nanosensing technologies have emerged as innovative approaches for the sensitive and rapid detection of tramadol at the nanoscale. Over the past decade, extensive advancements in nanosensor development have demonstrated their potential to overcome the limitations of conventional methods. This paper aims to introduce and discuss recently developed nanosensors specifically designed for tramadol detection, highlighting their significance in pharmacology, forensic medicine, and point-of-care (POC) applications. By providing enhanced sensitivity, specificity, and real-time analysis, these nanosensing techniques signify a groundbreaking advancement in the efficient monitoring and management of tramadol usage.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"576 ","pages":"Article 120414"},"PeriodicalIF":3.2,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144195809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biomarkers in liver regeneration","authors":"Radjabov Akhtam ,&nbsp;Shavazi Nargiz Nuraliyevna ,&nbsp;Mustafa Jawad Kadham ,&nbsp;Kosimova Shairakhon Mirzakhamitovna ,&nbsp;Rasulova Mokhidil Tursunaliyevna ,&nbsp;Khujaeva Shakhnoz ,&nbsp;Turabekov Shakhzod ,&nbsp;Bobojonov Otabek ,&nbsp;Matkarimov Inomjon Baxtiyorovich ,&nbsp;Akhmedova Feruzakhon Shakhboskhanovna ,&nbsp;Boymatova Zulxumorxon ,&nbsp;Ismoilova Muazzamxon Isroilovna ,&nbsp;Nilufar Rakhmonkulova Khodji-Akbarovna","doi":"10.1016/j.cca.2025.120413","DOIUrl":"10.1016/j.cca.2025.120413","url":null,"abstract":"<div><div>Liver regeneration is a complex and tightly regulated process essential for maintaining organ function following injury or surgical resection. This work explores the molecular mechanisms and key biomarkers involved in liver regeneration, highlighting their role in monitoring, predicting, and enhancing hepatic recovery. Conventional liver function tests, such as ALT and AST, provide insights into liver injury but lack specificity regarding regenerative capacity. Emerging biomarkers, including miRNAs, nuclear receptors, and native peptides, offer a more dynamic assessment of liver regeneration. Additionally, metabolomic and transcriptomic analyses revealed crucial pathways that drive hepatocyte proliferation and tissue repair. Understanding these biomarkers and regulatory networks is vital for improving clinical outcomes, preventing complications such as posthepatectomy liver failure, and advancing therapeutic strategies for liver diseases.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"576 ","pages":"Article 120413"},"PeriodicalIF":3.2,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144215105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Non-coding RNA biomarkers in basal-like breast cancer","authors":"Haider Ali ,&nbsp;Nawaid Hussain Khan ,&nbsp;Dalila Cano ,&nbsp;Guadalupe Cano ,&nbsp;Meliha Celik ,&nbsp;Sama Lilo ,&nbsp;Angel Fabia ,&nbsp;Yama A. ,&nbsp;Efrain Gudino ,&nbsp;Beyza Nur Beker","doi":"10.1016/j.cca.2025.120408","DOIUrl":"10.1016/j.cca.2025.120408","url":null,"abstract":"<div><div>Basal-like breast cancer (BLBC) is a highly aggressive molecular subtype characterized by poor prognosis and limited targeted treatment options. Clinicians face challenges in early diagnosis and precise prognostic stratification, necessitating the discovery of novel biomarkers and therapeutic targets. Non-coding RNAs (ncRNAs), including microRNAs (miRNAs), long non-coding RNAs (lncRNAs), small interfering RNAs (siRNAs), and circular RNAs (circRNAs), have emerged as crucial regulators of breast luminal B cancer (BLBC) tumorigenesis and progression. Their subtype-specific expression and remarkable stability in body fluids make them promising candidates for minimally invasive biomarkers in clinical chemistry, enabling the early detection, prediction of prognosis, and monitoring of therapeutic response. Additionally, ncRNA-based therapeutics offer innovative strategies to overcome resistance and improve treatment efficacy. This review comprehensively synthesises the latest advances in understanding non-coding RNA (ncRNA) biology in breast luminal B-like cancer (BLBC), focusing on their roles in key oncogenic and tumour-suppressive pathways. We highlight the translational potential of ncRNAs as diagnostic and prognostic biomarkers and discuss emerging therapeutic applications alongside current challenges such as assay standardisation and delivery optimisation. The novelty of this review lies in its integrative approach, bridging molecular mechanisms with clinical implications to guide future research and clinical translation. We aim to provide a critical resource that supports the development of ncRNA-based precision medicine approaches to improve the management and outcomes of patients with basal-like breast cancer.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"576 ","pages":"Article 120408"},"PeriodicalIF":3.2,"publicationDate":"2025-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144195808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immuno-PCR: Advancements, and applications for infectious diseases diagnosis","authors":"Ayushi Kaur Bedi,&nbsp;Monika Sharma,&nbsp;Sadhna Sharma","doi":"10.1016/j.cca.2025.120409","DOIUrl":"10.1016/j.cca.2025.120409","url":null,"abstract":"<div><div>Immuno-polymerase chain reaction (I-PCR) is a hybrid technique that combines the specificity of immunoassays with the amplification power of polymerase chain reaction for highly sensitive detection of Infectious Diseases Biomarkers. Since its introduction, I-PCR has evolved through advances such as the introduction of universal streptavidin–biotin systems, nanoparticle-based amplification, magnetic bead-assisted formats and the adoption of real-time and digital PCR readouts. These improvements have enabled detection limits significantly lower than traditional immunoassays, enabling its effective application in detecting viral, bacterial, parasitic, prion, and fungal antigens, as well as host antibodies, with detection limits reaching femtogram levels. However, clinical translation remains restricted by assay complexity, background signal amplification, and the reliance on thermal cyclers and specialized equipment. Future developments focusing on simplifying assay workflows, optimizing DNA-antibody conjugation, implementing isothermal amplification methods, and designing multiplexed point-of-care diagnostic platforms are essential to overcome current limitations. Addressing these challenges through continued innovation is essential to completely harness the potential of I-PCR as a highly sensitive, rapid, and accessible diagnostic platform across diverse healthcare settings.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"576 ","pages":"Article 120409"},"PeriodicalIF":3.2,"publicationDate":"2025-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144207803","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"MicroRNA biosensors for detection of Alzheimer’s disease","authors":"Asma Vafadar ,&nbsp;Mohammad Younesi ,&nbsp;Mohammad Ehsan Maddahi ,&nbsp;Sajad Ehtiati ,&nbsp;Hossein Moradi Kazerouni ,&nbsp;Faranak moradi khalaj ,&nbsp;Hasan Ghasemi ,&nbsp;Amir Savardashtaki","doi":"10.1016/j.cca.2025.120410","DOIUrl":"10.1016/j.cca.2025.120410","url":null,"abstract":"<div><div>Alzheimer’s disease (AD) is a critical global health problem characterized by cognitive degeneration and memory loss. Recent advancements in MicroRNA (miRNA) research have revealed their crucial role in AD development, Leading the way for early diagnosis and targeted treatments. Nanomaterials, renowned for their exceptional properties, have been integrated into biosensors to create highly sensitive and specific diagnostic tools. Among these, electrochemical biosensors, known for their simplicity and affordability, are particularly promising for clinical applications and point-of-care diagnostics. This review focuses on the application of miR-based electrochemical biosensors in early AD detection. We explore the innovative use of nanoparticles to enhance the sensitivity and specificity of these biosensors.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"576 ","pages":"Article 120410"},"PeriodicalIF":3.2,"publicationDate":"2025-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144205207","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Screening key genes differentially expressed in ankylosing spondylitis based on bioinformatics analysis and its clinical correlation study","authors":"Ziqi Li ,&nbsp;Xiaoya Sun ,&nbsp;Yanyu Zhao ,&nbsp;Yuxin Ren ,&nbsp;Hanqing Wu ,&nbsp;Longbao Xu ,&nbsp;Guoqing Li ,&nbsp;Mengmeng Wang ,&nbsp;Faming Pan","doi":"10.1016/j.cca.2025.120411","DOIUrl":"10.1016/j.cca.2025.120411","url":null,"abstract":"<div><h3>Objective</h3><div>This study aimed to identify potential biomarkers for Ankylosing Spondylitis (AS) through integrated bioinformatics analysis and case-control validation, thereby providing a theoretical basis for understanding the underlying pathogenesis of AS.</div></div><div><h3>Methods</h3><div>We first performed a comprehensive bioinformatics analysis integrated with a literature review to identify key candidate genes. Following this, a case-control validation study was carried out to verify the differential expression of these genes.</div></div><div><h3>Results</h3><div>Sixty-one differentially expressed genes (DEGs) were initially screened, and four key genes, ID2, PRF1, GZMB, and S100A12, were screened through comprehensive analysis and reference to relevant literature. Data from the qRT-PCR analysis indicated that the expression levels of ID2, PRF1, and GZMB were significantly reduced in patients with AS. The area under the ROC curve (AUC) indicated that among the single genes, ID2 had the best diagnostic performance, and the combined diagnostic performance of the four key genes was superior to that of ID2 alone. ID2 might regulate the apoptotic process of downstream PRF1 and GZMB through natural killer cells and CD8 cytotoxic T lymphocytes, thereby participating in the pathogenesis of AS. Furthermore, this study found that S100A12, PRF1 and GZMB were associated with multiple clinical indicators that reflected the level of inflammation or disease activity.</div></div><div><h3>Conclusions</h3><div>We identified four key DEGs via bioinformatics analysis and further validated them in case-control studies. The results indicated that these DEGs might serve as potential molecular targets for the diagnosis and treatment of AS.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"576 ","pages":"Article 120411"},"PeriodicalIF":3.2,"publicationDate":"2025-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144205208","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unexploited opportunities in oral disease biosensors and digital health integration","authors":"Hichem Moulahoum,&nbsp;Faezeh Ghorbanizamani","doi":"10.1016/j.cca.2025.120401","DOIUrl":"10.1016/j.cca.2025.120401","url":null,"abstract":"<div><div>Oral pathologies such as oral cancer, oral potentially malignant disorders (OPMDs), oral squamous cell carcinoma (OSCC), represent significant global health challenges owing to their prevalence, complex management, and impact on patient quality of life. Traditional diagnostic approaches, though effective, are often limited by their invasiveness, lack of sensitivity, and inability to provide real-time monitoring. Biosensors, particularly colorimetric and electrochemical types, offer promising alternatives by enabling rapid, non-invasive detection of disease-related biomarkers in saliva or breath. However, current biosensor applications in oral health are predominantly designed for single-time measurements, with limited capabilities for continuous monitoring and integration with digital health platforms. This narrative review synthesizes literature published in the last 10 years from major databases, focusing on recent advances in salivary biosensors for oral disease monitoring, with emphasis on OSCC and OPMDs. The review also explores the emerging role of artificial intelligence and digital platforms in transforming biosensor data into clinically meaningful insights. Addressing these areas could enhance the practicality and accessibility of biosensors, offering a proactive approach to oral healthcare and improving patient outcomes. This paper underscores the need for interdisciplinary collaboration to bridge current technological gaps, paving the way for a future where personalized, preventative care in oral pathology becomes standard practice.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"576 ","pages":"Article 120401"},"PeriodicalIF":3.2,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144178820","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical laboratory directorship in Asia-Pacific and North America: Current practices and pathways to global framework development","authors":"Mohammad Erfan Zare ,&nbsp;Atefeh Nasir Kansestani ,&nbsp;Reza Meshkani ,&nbsp;Kannan Vaidyanathan ,&nbsp;Chao Qi ,&nbsp;Guangwei Dai ,&nbsp;Feng Zhao ,&nbsp;Rui An ,&nbsp;Jun Zhang","doi":"10.1016/j.cca.2025.120407","DOIUrl":"10.1016/j.cca.2025.120407","url":null,"abstract":"<div><div>Clinical laboratories are essential to modern healthcare, playing a critical role in diagnosing, monitoring, and managing diseases. Laboratory directors, as the highest authority in the laboratory, are responsible for overseeing operations, ensuring test accuracy, maintaining quality control, and safeguarding patient safety. These directors are highly qualified professionals, but the qualifications required for the role vary significantly across countries. In some countries, medical doctors (MDs) are the standard, while in others, non-MD clinical scientists are eligible for the position. This variation presents challenges, leading to ongoing discussions in scientific societies about the best pathways to prepare individuals for this critical role. This debate underscores the need to balance clinical expertise with specialized scientific knowledge to meet the evolving demands of laboratory medicine. To address these challenges, establishing a global common pathway for laboratory directorship qualifications is essential. Recognizing the diversity of qualification systems across countries is crucial for developing a pathway that can be globally adaptable and applicable to various healthcare contexts. Drawing inspiration from successful models around the world will be key in shaping such a framework. Europe, with its well-documented qualification frameworks, has made significant efforts toward harmonizing standards for laboratory directorship. However, data on qualification systems in regions like Asia-Pacific and North America remain limited. This review aims to evaluate the current qualification requirements in these regions, compare them to established models, and discuss the feasibility of creating a globally standardized pathway for laboratory director qualifications. The findings could serve as the foundation for developing a more detailed, common curriculum by international scientific societies such as the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC), addressing the demands of various countries.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"576 ","pages":"Article 120407"},"PeriodicalIF":3.2,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144198380","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"tRNA Fragments in Diabetes Mellitus","authors":"Jiqing Zhang ,&nbsp;Mu Liu ,&nbsp;Zhongjun Li","doi":"10.1016/j.cca.2025.120405","DOIUrl":"10.1016/j.cca.2025.120405","url":null,"abstract":"<div><div>This review summarizes the research progress on tRNA-derived small RNAs (tsRNAs) in diabetes mellitus and diabetic complications. tsRNAs, categorized into tRNA-derived stress-induced RNAs (tiRNAs) and tRNA-derived fragments (tRFs), are involved in gene expression, protein translation, apoptosis, and intercellular communication. As a class of regulatory non-coding RNAs, tsRNAs exhibit significant roles in diabetes mellitus. Specifically, tRF-1:31-Glu-CTC-1-M2 shows early diagnostic value in gestational diabetes mellitus (GDM), while 5′ValCAC combined with miR-23b-3p distinguishes maternally inherited diabetes from type 2 diabetes mellitus (T2DM) (AUC = 1.00). tsRNAs demonstrate specific expression in diabetic complications: tRF-3001a and tRF-30 are elevated in diabetic retinopathy (DR) vitreous samples and tRF-Gly-CCC-039 exacerbates diabetic foot ulcer (DFU) progression. Furthermore, specific fragments like 5′tiRNA-His-GTG and tiRNA-Val are implicated in neurovascular dysfunction during DR progression. These findings present novel insights into the precise diagnosis and therapeutic management of diabetes mellitus and diabetic complications, underscoring the considerable translational potential of tsRNAs in clinical applications.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"576 ","pages":"Article 120405"},"PeriodicalIF":3.2,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144168426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}